Glutamate receptor ionotropic AMPA · PROTEIN COMPLEX GROUP · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Glutamate receptor ionotropic AMPA shows approved-linked disease relevance led by epilepsy. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P48058. Start with epilepsy, then reuse UniProt P48058 as the stable protein anchor across project notes and exports.
Start with epilepsy, then reuse UniProt P48058 as the stable protein anchor across project notes and exports.
Glutamate receptor ionotropic AMPA shows approved-linked disease relevance led by epilepsy. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.
Start review with epilepsy because it currently carries approved-linked support. Linked drugs include PERAMPANEL, SELURAMPANEL, TOPIRAMATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyGlutamate receptor 4
Review this target as Glutamate receptor ionotropic AMPA, mapped to UniProt P48058. ChEMBL maps the protein component as Glutamate receptor 4. Sequence length is 902 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Glutamate receptor ionotropic AMPA as ChEMBL target CHEMBL2096670, mapped to UniProt P48058. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Glutamate receptor ionotropic AMPA is the right protein anchor across sources, using UniProt P48058 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why epilepsy is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Glutamate receptor ionotropic AMPA |
| Target Type | PROTEIN COMPLEX GROUP |
| Organism | Homo sapiens |
| UniProt | P48058 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Glutamate receptor 4 |
| UniProt Accession | P48058 |
| Component Type | Protein |
| Sequence Length | 902 aa |
Glutamate receptor 4
Review this target as Glutamate receptor ionotropic AMPA, mapped to UniProt P48058. ChEMBL maps the protein component as Glutamate receptor 4. Sequence length is 902 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Glutamate receptor ionotropic AMPA shows approved-linked disease relevance led by epilepsy. 5 more disease programs remain visible in the same review block.
Start review with epilepsy because it currently carries approved-linked support. Linked drugs include PERAMPANEL, SELURAMPANEL, TOPIRAMATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL12696 | 8.4 | Ki | 4.0 | Preclinical |
| CHEMBL82375 | 8.4 | Ki | 4.0 | Preclinical |
| CHEMBL84142 | 8.4 | Ki | 4.0 | Preclinical |
| CHEMBL13076 | 8.3 | Ki | 5.0 | Preclinical |
| CHEMBL273675 | 8.3 | Ki | 5.0 | Preclinical |
| CHEMBL309831 | 8.15 | Ki | 7.0 | Preclinical |
| CHEMBL12510 | 7.82 | Ki | 15.0 | Preclinical |
| CHEMBL188018 | 7.8 | Ki | 16.0 | Preclinical |
| CHEMBL13378 | 7.72 | IC50 | 19.0 | Preclinical |
| CHEMBL90251 | 7.72 | Ki | 19.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein complex format | 50 | 135 | 6.1 |
| cell-based format | 6 | 17 | 5.0 |
| tissue-based format | 3 | 4 | 5.9 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 2 | 0 | — |